Navigation Links
Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its,Ghrelin Antagonist Program at the American Diabetes Association's,Annual Meeting

nd debilitating metabolic disorders such as Type 2 diabetes and obesity," stated Peter DiStefano, Ph.D., Chief Scientific Officer. "We are rapidly advancing our EX-1350 ghrelin antagonist and plan to initiate Phase I testing early next year."

According to the International Diabetes Federation, Type 2 diabetes affects 195 million people worldwide, and the number of sufferers could top 330 million by 2025.

Elixir has filed broad intellectual property protection on all aspects of the ghrelin antagonist program including composition of matter protection covering five novel compound classes and their therapeutic uses.

About Elixir Pharmaceuticals

Elixir is a Cambridge, MA-based biopharmaceutical company focused on developing and commercializing drugs to treat and prevent metabolic disease, prevent age-related diseases, ultimately extending the quality and length of human life.

In addition to its ghrelin antagonist program, the Company has leveraged its knowledge of ghrelin biology and pharmacology by licensing a small molecule ghrelin agonist (designated EX-1314) from Bristol-Myers Squibb Company in April 2005. EX-1314 binds selectively to the ghrelin receptor and mimics the body's naturally occurring ghrelin. In doing so this novel, orally available agent is capable of stimulating appetite, gastric motility and the release of growth hormone. Elixir is currently in IND-enabling studies with EX-1314 targeting a variety of therapeutic indications.

Further, in March 2006, Elixir in-licensed North and South American rights to Glufast(R) (mitiglinide calcium hydrate), an insulin secretagogue, which lowers post-meal glucose levels by improving the body's own ability to produce insulin. Already marketed in Japan, Glufast has undergone extensive clinical development demonstrating the product's ability to safely and effectively treat Type 2 diabetes.

Elixir has also developed expertise and a broad IP portfolio of more than twenty p
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Elixir Pharmaceuticals Announces Clinical Data at American Diabetes Association Conference Highlighting Ability of Glufast to Maintain Glycemic Control in Patients with Type 2 Diabetes
2. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
Post Your Comments:
(Date:11/30/2008)... , CHICAGO, Dec. 1 O...cerebral blood flow and a greater number of small ...presented today at the annual meeting of the Radio... The study, conducted at the University of Nort... compare brain scans of older adults who exercise ...
(Date:11/28/2008)...APOLIS, Nov. 28 Eli Lill...pplemental New Drug Application (sNDA) from,the U...a(R) (duloxetine HCl),for the management of chron...n,the first half of 2009, adding data from a rece...hritis pain of the knee. , The decision doe...
(Date:11/26/2008)...sed information density, automation and intelligen...n ultrasound to an all new level , , CHICAG...s Healthcare ( www.siemens.com/healthcare ) hi...ume Scanner (ABVS)(1), the world,s first multi-us...he 94th Scientific Assembly and Annual Meeting of ...
(Date:11/25/2008)...ILLE, Ky., Nov. 25 Klei...eons performed the fifth U.S. hand transplant on M... Louisville,s Jewish Hospital Hand Care Center on ...an around noon and was completed shortly after 9 p...ttp://www.newscom.com/cgi-bin/prnh/20081125/DC4855...
Breaking Medicine Technology:Exercise Helps Prevent Age-Related Brain Changes in Older Adults 2Exercise Helps Prevent Age-Related Brain Changes in Older Adults 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 4Siemens Introduces New Standard of Care for Breast Ultrasound 2Siemens Introduces New Standard of Care for Breast Ultrasound 3Siemens Introduces New Standard of Care for Breast Ultrasound 4Siemens Introduces New Standard of Care for Breast Ultrasound 5Kleinert Kutz Hand Surgeons Perform Fifth U.S. Hand Transplant in Record Time at Jewish Hospital Hand Care Center 2Kleinert Kutz Hand Surgeons Perform Fifth U.S. Hand Transplant in Record Time at Jewish Hospital Hand Care Center 3VIE Healthcare Expands Its Operations in the Midwest and Obtains First Local Client 14637 1VIE Healthcare Expands Its Operations in the Midwest and Obtains First Local Client 14637 2CVS Caremark Corp to Pay 2436 7 Million to U S 23 States 26 D C to Settle Medicaid Prescription Drug Fraud Allegations 14636 1CVS Caremark Corp to Pay 2436 7 Million to U S 23 States 26 D C to Settle Medicaid Prescription Drug Fraud Allegations 14636 2AUDIO from Medialink and Kelloggs 3A A Blissful Way to Recommit to Your Resolution 14634 1New Foam Treatment for Varicose Veins 14633 1New Foam Treatment for Varicose Veins 14633 2
...re/ -- Accera, Inc.,today is presenting data from ...trial of AC-1202 (Ketasyn) in Alzheimer,s disease ...l Conference on,Prevention of Dementia in Washingt...linical and preclinical studies, AC-1202 was,shown...y and,cognition of subjects of a particular pharma...
...2007 - Critical,Therapeutics, Inc. (Nasdaq: CRTX) ...otal Phase III clinical trial of ZYFLO CR(TM),(zil...ssue of the,Journal of Asthma. ZYFLO CR was approv...on May 30, 2007. Critical Therapeutics,together w...cts to,begin marketing ZYFLO CR in the U.S. in the...
Other Medicine Technology:Accera, Inc. Announces Open-Label Data from Phase II Study in,Alzheimer's Disease at International Conference on Prevention of,Dementia 2Accera, Inc. Announces Open-Label Data from Phase II Study in,Alzheimer's Disease at International Conference on Prevention of,Dementia 3Accera, Inc. Announces Open-Label Data from Phase II Study in,Alzheimer's Disease at International Conference on Prevention of,Dementia 4Critical Therapeutics Announces the Publication of Data for ZyfloCR,(Zileuton) Extended-Release Tablets in the Journal of Asthma 2Critical Therapeutics Announces the Publication of Data for ZyfloCR,(Zileuton) Extended-Release Tablets in the Journal of Asthma 3Critical Therapeutics Announces the Publication of Data for ZyfloCR,(Zileuton) Extended-Release Tablets in the Journal of Asthma 4Critical Therapeutics Announces the Publication of Data for ZyfloCR,(Zileuton) Extended-Release Tablets in the Journal of Asthma 5
(Date:12/2/2008)... Trials of tasimelteon show it could aid shift wo...ESDAY, Dec. 2 (HealthDay News) -- The experimental...aused by jet lag or night shifts, according to the...e II study included 39 people randomly assigned to... mg of tasimelteon, or a placebo. They were monito...
(Date:12/2/2008)... ORLANDO, Fla., Dec. 2 MEDai, Inc...care solutions provider, has added a new module,t...ons. The new stand-alone,module monitors a popul...delines and alerts stakeholders when there has bee...e Risk Navigator Guidelines(TM) provides,real-tim...
(Date:12/2/2008)... -Survey Reveals Nearly Half Have Skipped Medical...., Dec. 2 A new survey ...urce Center (NWHRC) highlights another troubling a...have failed to seek health care for themselves or ...ate that many women say their health has gotten wo...
(Date:12/2/2008)... MALVERN, Pa., Dec. 2 Arlington M...ket intelligence for the pharmaceutical and diagno...Janssen Pharmaceuticals, Levaquin,is the preferre... general,medical-surgical hospitals in the United...lung, sinus, skin and urinary tract infections cau...
Breaking Medicine News(10 mins):Health News:Drug Effective for Temporary Sleep Disruptions 2Health News:MEDai Evidence-Based Guideline Reporting Provides Decision Support at Point of Care 2Health News:Rising Health Costs Prompt Women to Neglect Health 2Health News:Rising Health Costs Prompt Women to Neglect Health 3Health News:Rising Health Costs Prompt Women to Neglect Health 4Health News:Levaquin is the Preferred Quinolone Among More Than Half of All General Medical-Surgical Hospitals in the United States 2
... Holtgrave, PhD, an expert on HIV prevention at th... a targeted campaign of testing and counseling aim... more effective than the mass patient screening pr...rol and Prevention (CDC). Holtgraves study is the...
...issue of CHEST, reports that children receiving an...r risk for developing asthma by age 7 than those ...oubled in children receiving antibiotics for nonre...ldren who received multiple antibiotic courses and...
... the issue of Neurology, the scientific journal of...easily distressed and have more negative emotions ...ore easygoing people. In the study, those who mos...ch as depression and anxiety were 40 percent more ...
...es re-sat their examinations Monday after a cheati...lts, an official said Monday . Lawyers hired by th...hools (CGFNS) acted as observers at examination ce...vao. Labour Secretary Arturo Brion said the gradu...
Other Medicine News:Health News:Targeted HIV Testing An Effective Way to Screen HIV Patients 2Health News:Antibiotic Use in Infants may Lead to Asthma. 2Health News:Pessimists may Develop More Memory Problems 2Health News:Philippine Nurses Re-sit Scandal-tainted Exams 2
Cold light source single outlet.
Cold light source triple outlet.
Cold light source single outlet.
The 9100 is a truly affordable 100 Watt xenon light source providing accurate color and brightness. This xenon light source is ideal for surgery centers, evaluations or general office use.
Medicine Products: